Abstract
BackgroundCabazitaxel has been approved as combination treatment with prednisone in patients with metastatic prostate cancer (MPC) refractory to hormone treatment previously treated with docetaxel.PurposeTo analyse the effectiveness and safety of...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: European Journal of Hospital Pharmacy: Science and Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.